Antibodies, together with viral 'inducers,' found to control HIV in mice

August 14, 2014, Rockefeller University
Credit: Martha Sexton/public domain

Although HIV can now be effectively suppressed using anti-retroviral drugs, it still comes surging back the moment the flow of drugs is stopped. Latent reservoirs of HIV-infected cells, invisible to the body's immune system and unreachable by pharmaceuticals, ensure that the infection will rebound after therapy is terminated.

But a new strategy devised by researchers at Rockefeller University harnesses the power of broadly against HIV, along with a combination of compounds that induce viral transcription, in order to attack these latent reservoirs of cells in an approach termed "shock and kill." In tests on mice, 57 percent of animals treated in this way did not have the expected resurgence of virus in their blood after their treatment ended.

"This is the first time that any combination of agents has been found to prevent viral rebound in any animal model," says Nussenzweig.

Three Rockefeller labs collaborated on the study: Michel C. Nussenzweig's Laboratory of Molecular Immunology; Alexander Tarakhovsky's Laboratory of Immune Cell Epigenetics and Signaling; and Jeffrey V. Ravetch's Leonard Wagner Laboratory of Molecular Genetics and Immunology. The findings are published August 14 in Cell.

The problematic latent reservoirs of HIV-infected cells are established very early in the infections, possibly even before tests can detect the presence of the virus, and current drug therapies are unable to kill the latent cells.

"The latent reservoir remains the major barrier to curing HIV-1 infection," says Nussenzweig, who is the Zanvil A. Cohn and Ralph M. Steinman Professor and a Howard Hughes Medical Institute investigator. "Our finding suggests that antibodies could play a significant role in disrupting the establishment and maintenance of the latent reservoir, which is believed to be a necessary step to curing patients of HIV-1."

The Nussenzweig lab has worked for several years on broadly neutralizing antibodies, a recently discovered subset of antibodies with an unusually high ability to recognize HIV consistently despite the virus's ability to rapidly mutate. Broadly neutralizing antibodies have shown great promise for treating HIV infection in mouse and monkey models of HIV. But by themselves they suffered the same problem that plagued other therapies: when you stop administering them, the virus rebounds.

Counterintuitively, the key to success in this instance was combining broadly neutralizing antibodies with viral inducers, compounds that prompt latent viruses to become active by promoting the transcription of their DNA. The idea is to eliminate the invisibility of the latent reservoir while simultaneously attacking the virus. More than half of the mice that received broadly neutralizing antibodies along with a cocktail of three viral inducers had no viral rebound at all, even three-and-a-half months after their last injection. (Broadly neutralizing antibodies alone, or even in combination with a single viral inducer, did not have this effect, nor did combinations of anti-retroviral drugs and viral inducers that have been attempted in the past.)

The researchers say that one reason broadly neutralizing antibodies may have succeeded where traditional drugs have failed is their ability to directly harness the power of the body's own using Fc receptors, which occur on a wide variety of immune system attack cells and help them precisely target the infection.

"A big surprise in this study was the important role the Fc part of the antibody played in amplifying the potency of ," says Ravetch, who is Theresa and Eugene M. Lang Professor. "Their effect in neutralizing latent reservoirs of HIV-1 was largely driven by Fc-receptor binding."

Explore further: Mechanism found for development of protective HIV antibodies

More information: Cell, Halper-Stromberg et al.: "Broadly Neutralizing Antibodies and Viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice." www.cell.com/cell/abstract/S0092-8674(14)00993-3

Related Stories

Mechanism found for development of protective HIV antibodies

July 24, 2014
Scientists at Duke Medicine have found an immunologic mechanism that makes broadly neutralizing antibodies in people who are HIV-1 infected.

Researchers use antibody treatment to protect humanized mice from HIV

February 11, 2014
NIH-funded scientists have shown that boosting the production of certain broadly neutralizing antibodies can protect humanized mice from both intravenous and vaginal infection with HIV. Humanized mice have immune systems ...

Researchers discuss challenges to developing broadly protective HIV vaccines

September 7, 2011
The human body can produce powerful antibodies that shield cells in the laboratory against infection by an array of HIV strains. In people, however, recent research shows that these broadly neutralizing antibodies are not ...

Scientists identify broad and potent HIV antibodies that mimic CD4 binding

July 20, 2011
In a finding that may be good news for scientists developing HIV vaccines and therapies, a team of researchers at The Rockefeller University and the Howard Hughes Medical Institute have found a way to investigate the broadly ...

New research offers hope for HIV vaccine development

August 13, 2014
In a scientific discovery that has significant implications for HIV vaccine development, collaborators at the Boston University School of Medicine (BUSM) and Duke University School of Medicine have uncovered novel properties ...

Potent antibodies neutralize HIV and could offer new therapy, study finds

November 7, 2012
(Medical Xpress)—Having HIV/AIDS is no longer a death sentence, but it's still a lifelong illness that requires an expensive daily cocktail of drugs—and it means tolerating those drugs' side effects and running the risk ...

Recommended for you

HIV-1 genetic diversity is higher in vaginal tract than in blood during early infection

January 18, 2018
A first-of-its-kind study has found that the genetic diversity of human immunodeficiency virus type 1 (HIV-1) is higher in the vaginal tract than in the blood stream during early infection. This finding, published in PLOS ...

War in Ukraine has escalated HIV spread in the country: study

January 15, 2018
Conflict in Ukraine has increased the risk of HIV outbreaks throughout the country as displaced HIV-infected people move from war-affected regions to areas with higher risk of transmission, according to analysis by scientists.

Researchers offer new model for uncovering true HIV mortality rates in Zambia

January 12, 2018
A new study that seeks to better ascertain HIV mortality rates in Zambia could provide a model for improved national and regional surveillance approaches, and ultimately, more effective HIV treatment strategies.

New drug capsule may allow weekly HIV treatment

January 9, 2018
Researchers at MIT and Brigham and Women's Hospital have developed a capsule that can deliver a week's worth of HIV drugs in a single dose. This advance could make it much easier for patients to adhere to the strict schedule ...

New long-acting, less-toxic HIV drug suppresses virus in humanized mice

January 8, 2018
A team of Yale researchers tested a new chemical compound that suppresses HIV, protects immune cells, and remains effective for weeks with a single dose. In animal experiments, the compound proved to be a promising new candidate ...

Usage remains low for pill that can prevent HIV infection

January 8, 2018
From gritty neighborhoods in New York and Los Angeles to clinics in Kenya and Brazil, health workers are trying to popularize a pill that has proven highly effective in preventing HIV but which—in their view—remains woefully ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.